Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).
Xu X, Poulsen KL, Wu L, Liu S, Miyata T, Song Q, Wei Q, Zhao C, Lin C, Yang J. · 2022
Read Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). by Xu X, Poulsen KL, Wu L, Liu S, Miyata T, Song Q, Wei Q, Zhao C, Lin C, Yang J. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9376100.txt.
Introduction
Xu and co-authors review drug targets and new signal paths in fatty liver disease not tied to alcohol. The condition now leads liver disease causes worldwide. Its advanced form can run to cirrhosis and liver cancer. Lifestyle change remains the main proven defense, and approved drugs are still scarce.
The review covers causes, candidate targets, and drugs in trials or patents. Themes include diabetes links, fat handling in the liver, inflammation, and scarring. A broken gut-liver axis and microbe products help drive the disease. Tiny vesicles from cells carry signals that load fat and wake scar-forming cells. Cell therapy and gene approaches close the survey. The authors favor pairing drugs with personal matching of patients.
Catalog record
| CREATOR | Xu X, Poulsen KL, Wu L, Liu S, Miyata T, Song Q, Wei Q, Zhao C, Lin C, Yang J. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 255 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |